Abstract: There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers.
Type:
Grant
Filed:
April 7, 2015
Date of Patent:
September 7, 2021
Assignee:
Sorrento Therapeutics, Inc.
Inventors:
Randy Gastwirt, Heyue Zhou, John Dixon Gray, Guodi Lu
Abstract: An implantable delivery device and method for utilizing the device to delivery a bioactive agent to a subject in need thereof is described. The device includes a pattern of structures fabricated on a surface of the device to form a nanotopography. A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. The device may be located adjacent tissue such as an endovascular implant or a perivascular implant, and may deliver the bioactive agent without triggering an immune or foreign body response to the bioactive agent.
Type:
Grant
Filed:
October 16, 2012
Date of Patent:
September 7, 2021
Assignee:
SORRENTO THERAPEUTICS, INC.
Inventors:
Jeremy Ollerenshaw, Emily Reichart, Russell F. Ross
Abstract: A method for increasing permeability of a cellular layer of epithelial cells includes contacting the cellular layer with a nanostructured surface including a plurality of first nanostructures arranged thereon and projecting outward therefrom. A fractal dimension of the plurality of nanostructures is greater than 1. The permeability of the cellular layer by a compound is increased as compared to the permeability of the cellular layer prior to contact with the surface.
Abstract: This invention provides small molecule Myc-inhibitors. Also provided in the invention are therapeutic applications of these compounds for treating Myc-driven cancer and other related methods.
Type:
Grant
Filed:
December 10, 2014
Date of Patent:
July 20, 2021
Assignees:
The Scripps Research Institute, Sorrento Therapeutics, Inc.
Inventors:
Peter K. Vogt, Francis X. Tavares, Kim D. Janda
Abstract: A receptacle, which may be suitable for use as a portion of a transdermal drug delivery apparatus, may include a housing for being fastened to the user, a force provider that is elastic, at least one deformable component, and a microneedle assembly movably mounted to the housing for moving inwardly and outwardly relative to the housing. The force provider may be positioned between the housing and the microneedle assembly for forcing the microneedle assembly outwardly relative to the housing and against the skin of the user. The at least one deformable component may be connected between the microneedle assembly and the housing for both allowing relative movement between the microneedle assembly and the housing, and at least partially restricting the microneedle assembly from falling away from the housing.
Type:
Grant
Filed:
April 29, 2015
Date of Patent:
June 22, 2021
Assignee:
Sorrento Therapeutics, Inc.
Inventors:
Andrew T. Baker, Elizabeth Deibler Gadsby, Russell F. Ross, Luke Hagan
Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.
Type:
Grant
Filed:
August 24, 2018
Date of Patent:
June 8, 2021
Assignee:
Sorrento Therapeutics, Inc.
Inventors:
Heyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann
Abstract: There is disclosed anti-PD-L1 IgG class antibodies that have an improved ability to be manufactured at higher yields. More specifically, there is disclosed human antibodies that bind PD-L1, PD-L1-binding fragments that can be manufactured at higher yields.
Abstract: Provided herein are cell penetrating compounds having the Formula I: where, generally, each T is a thiol reactive group (e.g., a phosphorothioate), each L is a linker (e.g., a linear alkyl), and Y is a biologic (e.g., an antibody). Also provided are pharmaceutical compositions including the cell penetrating compounds, and methods of delivering the compound into a cell.
Type:
Application
Filed:
January 20, 2021
Publication date:
May 13, 2021
Applicant:
Sorrento Therapeutics, Inc.
Inventors:
Yanwen Fu, Gunnar F. Kaufmann, Heehyoung Lee, Tong Zhu, Henry Hongjun Ji
Abstract: The present disclosure provides anti-CD38 IgG class antibody having improved ability to be manufactured at higher yields compared to the parent antibody having the original wild type sequence. The present disclosure provides a mutated antibody light chain that reduces cleavage heterogeneity for improved production of a homogeneous population of antibody light chains.
Type:
Application
Filed:
December 18, 2020
Publication date:
May 6, 2021
Applicant:
Sorrento Therapeutics, Inc.
Inventors:
Barbara A. Swanson, Heyue Zhou, Jian Cao
Abstract: A transdermal drug delivery device is disclosed that may comprise a housing including an upper housing portion and a lower housing portion. The lower housing portion may define a bottom surface including skin attachment means for releasably attaching the lower housing portion to skin of a user. The upper housing portion may at least partially surround a central region of the device. The device may also include a microneedle assembly and a reservoir disposed within the central region. The reservoir may be in fluid communication with the microneedle assembly. Additionally, the device may include a pushing element disposed above the microneedle assembly within the central region. The pushing element may be configured to provide a continuous bilateral force having a downward component transmitted through the microneedle assembly and an upward component transmitted through the skin attachment means.
Type:
Grant
Filed:
December 18, 2018
Date of Patent:
March 23, 2021
Assignee:
SORRENTO THERAPEUTICS, INC.
Inventors:
Russell F. Ross, Luke Hagan, Alexander Malkin, Derek Hatchett, Jacob Marks, Thomas Lutzow
Abstract: A cartridge, which may be suitable for use as a portion of a transdermal drug delivery apparatus, may include a body at least partially defining an interior for containing fluid for being delivered by the transdermal drug delivery apparatus. The body may also at least partially define first and second openings to the interior of the body, wherein the first and second openings are respectively proximate opposite first and second ends of the body. The cartridge may also include a self-sealing member at least partially closing the first opening, and a movable member at least partially closing the second opening, wherein at least a portion of the movable member is for being urged into the interior of the body for increasing pressure within the interior of the body.
Type:
Grant
Filed:
October 25, 2018
Date of Patent:
March 9, 2021
Assignee:
SORRENTO THERAPEUTICS, INC.
Inventors:
Andrew T. Baker, Elizabeth Deibler Gadsby, Russell F. Ross, Luke Hagan
Abstract: There is disclosed compositions and methods relating to or derived from anti-CD123 antibodies. More specifically, there is disclosed fully human antibodies that bind CD123, CD123-antibody binding fragments and derivatives of such antibodies, and CD123-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.
Abstract: Provided are bispecific conjugates having the general formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the treatment of cancer.
Type:
Application
Filed:
August 31, 2020
Publication date:
February 25, 2021
Applicant:
Sorrento Therapeutics, Inc.
Inventors:
James T. Patterson, Gunnar F. Kaufmann, Yanwen Fu, Tong Zhu
Abstract: There is disclosed compositions and methods relating to or derived from anti-TIM3 antibodies. More specifically, there is disclosed fully human antibodies that bind TIM3, TIM3-antibody binding fragments and derivatives of such antibodies, and TIM3-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.
Type:
Grant
Filed:
December 14, 2017
Date of Patent:
February 23, 2021
Assignee:
Sorrento Therapeutics, Inc.
Inventors:
John Dixon Gray, Heyue Zhou, Irina Krapf
Abstract: Provided herein are cell penetrating compounds having the Formula I: where, generally, each T is a thiol reactive group (e.g., a phosphorothioate), each L is a linker (e.g., a linear alkyl), and Y is a biologic (e.g., an antibody). Also provided are pharmaceutical compositions including the cell penetrating compounds, and methods of delivering the compound into a cell.
Type:
Grant
Filed:
June 27, 2019
Date of Patent:
February 23, 2021
Assignee:
Sorrento Therapeutics, Inc.
Inventors:
Yanwen Fu, Gunnar F. Kaufmann, Heehyoung Lee, Tong Zhu, Henry Hongjun Ji
Abstract: There is disclosed anti-PD-L1 IgG class antibodies that have an improved ability to be manufactured at higher yields. More specifically, there is disclosed human antibodies that bind PD-L1, PD-L1-binding fragments that can be manufactured at higher yields.
Abstract: A gas extraction device for a fluid delivery apparatus includes a first layer and a vent membrane coupled to the first layer. The vent membrane enables a gas to pass through the vent membrane and prevents a fluid from passing through the vent membrane. The gas extraction device also includes a second layer coupled to the vent membrane opposite the first layer. The second layer has a first channel formed therethrough. In addition, the gas extraction device includes an impermeable membrane coupled to the second layer opposite the vent membrane. The first channel is configured to receive a fluid having a gas dispersed therein. The fluid is pressurized to move the fluid through the first channel against the vent membrane and to move the gas through the vent membrane.
Type:
Grant
Filed:
January 9, 2020
Date of Patent:
February 2, 2021
Assignee:
Sorrento Therapeutics, Inc.
Inventors:
Russell F. Ross, Andrew T. Baker, Luke Hagan
Abstract: There is disclosed an improved ADC (antibody drug conjugate) type composition having at least two different drug payloads conjugated to a single targeting protein. More specifically, the present disclosure attaches a first drug conjugate to a dual Cysteine residue on a targeting protein and a second drug conjugate with a different drug to a Lys residue on the targeting protein.
Type:
Application
Filed:
September 29, 2020
Publication date:
January 21, 2021
Applicant:
Sorrento Therapeutics, Inc.
Inventors:
Zhenwei Miao, Gang Chen, Tong Zhu, Alisher B. Khasanov, Yufeng Hong, Hong D. Zhang, Alexander Chucholowski